Get started
Author

Joep H. G. Scholl

Observed names: J H G Scholl, J. Scholl, Joep H.G. Scholl, Joep Scholl, Scholl, JHG, Scholl, Joep
ORCID: 0000-0002-9222-5965
Observed ORCID: 0000-0002-9222-5965
OpenAlex ID: A5022033197
Nanomedicinal products: a survey on specific toxicity and side effects
2017 · Walter Brand, Cornelle W Noorlander, et al. · International Journal of Nanomedicine · 72
PDF
Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors
2018 · Corine Ekhart, Florence van Hunsel, et al. · Drug Safety · 37
PDF
Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
2015 · Kevin Klein, Joep H. G. Scholl, et al. · Drug Safety · 36
PDF
Adverse Drug Reactions to Opioids: A Study in a National Pharmacovigilance Database
2023 · Moa Gustafsson, Cristiano Matos, et al. · Drug Safety · 34
Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database
2022 · Carolina Valeiro, Cristiano Matos, et al. · Drug Safety · 34
When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal Detection
2017 · Kevin Klein, Joep H.G. Scholl, et al. · Clinical Pharmacology & Therapeutics · 28
The value of time‐to‐onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands
2016 · Joep H. G. Scholl, Eugène P. van Puijenbroek · Pharmacoepidemiology and Drug Safety · 26
PDF
Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non‐diabetic patients
2014 · Joep H. G. Scholl, Rike van Eekeren, et al. · British Journal of Clinical Pharmacology · 25
A prediction model‐based algorithm for computer‐assisted database screening of adverse drug reactions in the Netherlands
2017 · Joep H.G. Scholl, Florence P.A.M. van Hunsel, et al. · Pharmacoepidemiology and Drug Safety · 23
PDF
Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience
2022 · Ingrid Oosterhuis, Joep Scholl, et al. · Drug Safety · 20
PDF
Time to onset in statistical signal detection revisited: A follow‐up study in long‐term onset adverse drug reactions
2019 · Joep H.G. Scholl, Florence P.A.M. van Hunsel, et al. · Pharmacoepidemiology and Drug Safety · 11
PDF
Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands
2023 · Saskia C. van der Boor, Else T.J. Schmitz-de Vries, et al. · Vaccine · 9
PDF
Hearing Impairment Associated with Oral Terbinafine Use
2012 · Joep H. G. Scholl, Eugene P. van Puijenbroek · Drug Safety · 8
Parametric time-to-onset models were developed to improve causality assessment of adverse drug reactions from antidiabetic drugs
2015 · Joep H.G. Scholl, Peter M. van de Ven, et al. · Journal of Clinical Epidemiology · 7
PDF
Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands
2020 · Pieter J. Glerum, Marc Maliepaard, et al. · Clinical and Translational Science · 6
PDF
Impact of Regulatory Action on Dose Maximalization for Vitamin B6 Dietary Supplements on the Reporting Pattern for Neuropathy
2025 · Florence van Hunsel, Joep Scholl, et al. · Pharmacoepidemiology and Drug Safety · 5
PDF
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept
2023 · Kimberly Velthuis, Naomi T. Jessurun, et al. · Expert Opinion on Drug Safety · 5
Signal detection in pharmacovigilance: time for a new era?
2022 · Joep Scholl · University of Groningen research database (University of Groningen / Centre for Information Technology) · 2
PDF
Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases
2026 · Oskar Rachwal, Mar Gutiérrez-Lobón, et al. · Drug Safety · 1
PDF
Timing Matters: Exploring the Role of the Time to Onset in Recall Bias for Adverse Events Following Immunization (AEFIs) of COVID-19 Vaccines from Spontaneous Reports
2025 · Joep Scholl, Florence van Hunsel, et al. · Pharmacoepidemiology · 1
PDF
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study
2022 · Lieke H. Roest, Leanne J. Kosse, et al. · Expert Opinion on Drug Safety · 1
Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal
2026 · Michele Fusaroli, Joana Félix China, et al. · Drug Safety
PDF
Detecting drug-related problems following metabolic and bariatric surgery using pharmacovigilance databases
2026 · Cedric Lau, Robert M. Smeenk, et al. · International Journal of Obesity
Pos0621 Disease-specific Adverse Drug Reaction Profiles of Adalimumab and Etanercept as Reported by Immune-mediated Inflammatory Disease Patients
2021 · L. Roest, L. Kosse, et al. · Annals of the Rheumatic Diseases
Ab0196 Survival Analysis of Time to First Adverse Drug Reaction and Drug Survival in Rheumatoid Arthritis Patients Treated With Adalimumab and Etanercept
2021 · M. Nguyen, K. Velthuis, et al. · Annals of the Rheumatic Diseases
PDF
Works count: 32
Citation count: 391
H-index: 11
I10-index: 11
Year
Topic
Type